1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Safety and efficacy outcomes
Variable Value
Procedure 
    Patients (No.) 21
    Patients with technically feasible AVMs (No.) (%) 19 (90.5%)
    Procedure-related complications (No.) (%) 6 (28.6)
        Transient 4 (19.0)
        Permanent, nondisabling 0 (0)
        Permanent, disabling 1 (4.8)
        Death 1 (4.8)
        Non-neurologic 0 (0)
Follow-up 
    Immediate obliteration after procedure (No.) (%) 
        In 19 patients with technically feasible AVMs 16 (84.2)
        In all 21 patients 16 (76.2)
    Imaging follow-up of patients (No.) 14
        Follow-up time (median) (range) 5.5 (3–15)
        Obliteration at follow-up (No.) (%) 13 (92.9)
        Stable 1 (7.1)
        Recanalization 0 (0)
    Clinical follow-up of patients within 1 mo (No.) 21
        Events 6
        Stroke 6
        Others 0
    Clinical follow-up of patients beyond 1 mo (No.) 20
        The latest follow-up time (median) (range) 15 (2–26)
        Events (No.) 1
        Epilepsy 1
        Others 0
        The latest mRS 
            0–2 19
            3–5 1
            6 0